Pelizaeus Merzbacher disease

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Pelizaeus Merzbacher disease is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • PMD
  • Pelizaeus-Merzbacher disease
  • sclerosis, diffuse familial brain
  • sudanophilic leukodystrophy, Pelizaeus-Merzbacher type

Disorder Subdivisions

  • None

General Discussion

Pelizaeus-Merzbacher disease (PMD) is a rare X-linked genetic disorder affecting the central nervous system that is associated with abnormalities of the white matter of the brain and spinal cord. Symptoms develop due to lack of the fatty covering (myelin sheath) of nerve cell fibers. Many areas of the central nervous system may be affected, including the deep portions of the cerebrum (subcortical), cerebellum, brain stem and spinal cord. Signs may include the impaired ability to coordinate movement (ataxia), involuntary muscle spasms (spasticity) that result in slow, stiff movements of the legs, delays in reaching developmental milestones, and late onset loss of motor abilities and progressive deterioration of intellectual function. The neurologic signs of Pelizaeus-Merzbacher disease are usually slowly progressive.

Pelizaeus-Merzbacher disease is associated with abnormalities (mutations) in the PLP1 gene. Several forms of the disorder have been identified including classic PMD; connatal PMD; transitional PMD; and PLP1 null syndrome. Forms of complicated spastic paraparesis and pure spastic paraparesis (designated SPG2) are also caused by the PLP1 gene.


The signs of Pelizaeus-Merzbacher disease may vary widely from case to case. The signs of the classical form of PMD usually begin during early infancy, typically before 2 months of age. Initially, affected infants may fail to develop normal control of the head and eyes, specifically abnormal head bobbing and rapid, involuntary, jerky eye movements (nystagmus). Abnormally slow growth may also be an early sign.

As affected infants and children age, additional signs may become apparent, including muscle tremors, weakness, facial grimacing, lack of muscle tone (hypotonia), impaired ability to coordinate voluntary movements (ataxia), and/or impairment in the acquisition of skills requiring the coordination of muscular and mental activities (psychomotor retardation) including delays in reaching developmental milestones such as sitting, standing, and walking.

Affected individuals may also develop involuntary muscle spasms (spasticity) that result in slow, stiff movements of the legs and potentially partial paralysis of the arms and legs (spastic quadriparesis); abnormal, permanent fixation of certain joints (contractures); progressive degeneration of the nerves that lead to the eyes (optic atrophy); and/or difficulty speaking (dysarthria).

In some cases, as affected children age, nystagmus may disappear. Some children may also develop skeletal deformities Secondary to the severe spasticity that typically develops over time.

The signs of connatal PMD begin during the first few weeks of life. This form of the disorder is characterized by weakness, spasticity, stridor, nystagmus, and seizures. Severe dysphagia may also occur, necessitating gastrostomy feeding. Affected infants may also exhibit deterioration of mental functions and failure to reach developmental milestones such as speaking and walking. The progression of this form of Pelizaeus-Merzbacher disease is more rapid and severe than the classic form and is often fatal during childhood.

Transitional PMD is a form of Pelizaeus-Merzbacher disease intermediate between the classical and connatal forms. The signs are similar to those of the classical and connatal forms of the disorder. However, the rate of progression is faster than the classical form but slower than the connatal form. The PLP1 null syndrome is characterized by mild spastic quadriparesis, mild ataxia, absence of nystagmus during infancy and a mild demyelinating peripheral neuropathy. Patients with this form typically learn to walk, but deteriorate more rapidly beginning in late adolescence or early adulthood.

Female carriers of PMD-related PLP1 mutations may have mild to moderate signs of the disease.


Pelizaeus-Merzbacher disease is inherited as an X-linked genetic disorder. X-linked genetic disorders are conditions caused by an abnormal gene on the X chromosome and occur mostly in males. Females that have a disease gene present on one of their X chromosomes are carriers for that disorder. Carrier females usually do not display symptoms because females have two X chromosomes and one is inactivated so that the genes on that chromosome are nonfunctioning. It is usually the X chromosome with the abnormal gene that is inactivated. Males have one X chromosome that is inherited from their mother and if a male inherits an X chromosome that contains a disease gene he will develop the disease. Female carriers of an X-linked disorder have a 25% chance with each pregnancy to have a carrier daughter like themselves, a 25% chance to have a non-carrier daughter, a 25% chance to have a son affected with the disease and a 25% chance to have an unaffected son. Females from families where males have a milder phenotype, such as SPG2 or the PLP1 null syndrome, should be more cautiously counseled. In some of these families the disorder behaves more like an X-linked dominant disorder with reduced penetrance.

Males with X-linked disorders pass the disease gene to all of their daughters who will be carriers. A male cannot pass an X-linked gene to his sons because males always pass their Y chromosome instead of their X chromosome to male offspring.

The only gene that has been found to be associated with PMD is located on the long arm of the X chromosome (Xq21.3-q22) and called the proteolipid protein gene or PLP1. Approximately 5-20% of males with a syndrome consistent with PMD do not have a mutation in the PLP1 gene so other genes may also be related to this condition. Mutations in the GJC2 (autosomal recessive), SLC16A2/MCT8 (X-linked) and HSPD1/HSP60 (autosomal recessive) genes are recently described causes of Pelizaeus-Merzbacher-like disease (PMLD). Other PMLD genes very likely remain to be discovered. Spastic paraplegia 2 (SPG2) and Pelizaeus-Merzbacher disease result from different mutations of the same gene (allelic disorders) on the X chromosome.

Affected Populations

The classical form of Pelizaeus-Merzbacher disease affects males far more often than females. In rare cases, heterozygous females will exhibit some of the signs associated with the disorder.

The recessively inherited cases of acute infantile (connatal) Pelizaeus-Merzbacher disease affect males and females in equal numbers. Adult-onset Pelizaeus-Merzbacher disease affects males and females in equal numbers and symptoms generally begin during the 3rd or 4th decade of life.

Pelizaeus-Merzbacher disease is a rare disorder. Its prevalence in the general population is unknown but estimated as approximately 1 in 100,000 in the USA.

Standard Therapies


A diagnosis of Pelizaeus-Merzbacher disease may be suspected based upon a thorough clinical evaluation, a detailed patient history and a variety of specialized tests such as magnetic resonance imaging (MRI) to detect deficiency of white matter. Recognition of early myelination defects, such as lack of myelination in the cerebellum and brainstem, may aide in early diagnosis of the severe forms of PMD. Molecular genetic testing for the PLP1 gene is available to confirm the diagnosis.

Carrier testing is possible if a disease-causing mutation in the PLP1 gene has been identified in an affected family member.

Prenatal diagnosis and preimplantation genetic diagnosis is available if a PLP1 gene mutation is identified in an affected family member.


There is no standard treatment method or regimen for individuals with Pelizaeus-Merzbacher disease. Treatment is based upon specific symptoms present such as medications that prevent seizures or those used for movement disorders. Supportive care, including emotional support for family members, is recommended as needed.

Genetic Counseling is recommended for individuals affected with Pelizaeus-Merzbacher disease and their families.

Investigational Therapies

StemCells Inc., in conjunction with the UCSF Children's Hospital in San Francisco, is conducting a Phase I trial designed to assess the safety and preliminary effectiveness of HuCNS-SC cells (human neural stem cells) as a potential treatment for Pelizaeus-Merzbacher disease (PMD). The trial is expected to enroll four patients with the connatal type of PMD. For more information visit:

Information on current clinical trials is posted on the Internet at All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Toll-free: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, contact:



Adams, RD, et al., eds. Principles of Neurology. 6th ed. New York, NY: McGraw-Hill, Companies; 1997:944.

Behrman RE, ed. Nelson Textbook of Pediatrics, 15th ed. Philadelphia, PA: W.B. Saunders Company; 1996:1727.

Menkes JH, au., Pine JW, et al., eds. Textbook of Child Neurology, 5th ed. Baltimore, MD: Williams & Wilkins; 1995:190-91.


Vaurs-Barrière et al. Pelizaeus-Merzbacher-Like disease presentation of MCT8 mutated male subjects. Ann Neurol. 2009 Jan;65(1):114-8

Fattal-Valevski et al. Variable expression of a novel PLP1 mutation in members of a family with Pelizaeus-Merzbacher disease. J Child

Neurol. 2009 May;24(5):618-24

Orthmann-Murphy et al. Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations. Brain. 2009 Feb;132(Pt 2):426-38.

Magen et al. Mitochondrial hsp60 chaperonopathy causes an autosomal-recessive neurodegenerative disorder linked to brain hypomyelination and leukodystrophy. Am J Hum Genet. 2008 Jul;83(1):30-42.

Woodward KJ. The molecular and cellular defects underlying Pelizaeus-Merzbacher disease. Expert Rev Mol Med. 2008 May 19;10:e14

Henneke et al. GJA12 mutations are a rare cause of Pelizaeus-Merzbacher-like disease. Neurology. 2008 Mar 4;70(10):748-54

McGuire et al. The impact of Pelizaeus-Merzbacher disease on the family. Pediatr Neurol. 2007 Feb;36(2):101-5.

Garbern JY. Pelizaeus-Merzbacher disease: Genetic and cellular pathogenesis.

Cell Mol Life Sci. 2007 Jan;64(1):50-65.

Lee JA, et al. A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. Cell. 2007 Dec


Hurst et al. A. Quantifying the carrier female phenotype in Pelizaeus-Merzbacher disease. Genet Med. 2006 Jun;8(6):371-8.

Verlinsky et al. Preimplantation genetic diagnosis for Pelizaeus-Merzbacher disease with testing for age-related aneuploidies. Reprod Biomed. 2006 Jan;12(1):83-8.

Woodward et al. Heterogeneous duplications in patients with Pelizaeus-Merzbacher disease suggest a mechanism of coupled homologous and nonhomologous recombination. Am J Hum Genet. 2005 Dec;77(6):966-87

Wolf et al. Three or more copies of the proteolipid protein gene PLP1 cause

severe Pelizaeus-Merzbacher disease. Brain. 2005 Apr;128(Pt 4):743-51.

Koeppen AH. A brief history of Pelizaeus-Merzbacher disease and proteolipid

protein. J Neurol Sci. 2005 Feb 15;228(2):198-200

Uhlenberg et al. Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease. Am J Hum Genet. 2004 Aug;75(2):251-60.

Garbern J, Hobson G. Prenatal diagnosis of Pelizaeus-Merzbacher disease.

Prenat Diagn. 2002 Nov;22(11):1033-5

Garbern et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain. 2002 Mar;125(Pt 3):551-61.

Berger J, et al. Leukodystrophies: recent developments in genetics, molecular biology, pathogenesis, and treatment. Curr Opin Neurol. 2001;14:305-12.

Kurata K, et al. Clinical symptoms and characteristic MR spectroscopic findings in Pelizaeus-Merzbacher disease. No To Hattatsu. 2000;32:503-08.

Percy AK. Pelizaeus-Merzbacher disease: splice sites are nice sites for disease expression. Neurology. 2000;55:1072-73.

Spalice A, et al. Proton MR spectroscopy in connnatal Pelizaeus-Merzbacher disease. Pediatr Neurol. 2000;30:171-75.

Hobson GM, et al. Mutations in noncoding regions of the proteolipid protein gene in Pelizaeus-Merzbacher disease. Neurology. 2000;55:1089-96.

Wang PJ, et al. Duplication of proteolipid protein gene: a possible major cause of Pelizaeus-Merzbacher disease. Pediatr Neurol. 1997;17:125-28.

Apkarian P, et al. Visual evoked potential characteristics and early diagnosis of Pelizaeus- Merzbacher disease. Arch Neurol. 1993;50:981-85.

Scheffer IE, et al. Pelizaeus-Merzbacher disease: classical or connatal? Neuropediatrics. 1991;22:71-78.

Raskind WH, et al. Complete deletion of the proteolipid protein gene (PLP) in a family with X-linked Pelizaeus-Merzbacher disease. Am J Hum Genet. 1991;49:1355-60.

Gencic S, et al. Pelizaeus-Merzbacher disease: an X-linked neurologic disorder of myelin metabolism with a novel mutation in the gene encoding proteolipid protein. Am J Hum Genet. 1989;45:435-42.

Begleiter ML, et al. Autosomal recessive form of connatal Pelizaeus-Merzbacher disease. Am J Med Genet. 1989;33:311-13.

Cassidy SB, et al. Connatal Pelizaeus-Merzbacher disease: an autosomal recessive form. Pediatr Neurol. 1987;3:300-05.


Garbern JY, and Hobson GM. Updated 9/15/06. PLP1-Related Disorders. In GeneReviews at Genetests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2010. Available at Accessed 5/08.


CLIMB (Children Living with Inherited Metabolic Diseases)

Climb Building

176 Nantwich Road

Crewe, CW2 6BG

United Kingdom

Tel: 4408452412173

Fax: 4408452412174



March of Dimes Birth Defects Foundation

1275 Mamaroneck Avenue

White Plains, NY 10605

Tel: (914)997-4488

Fax: (914)997-4763


United Leukodystrophy Foundation

224 N. 2nd St.

Suite 2

DeKalb, IL 60115

Tel: (815)748-3211

Tel: (800)728-5483



ELA - European Association Against Leukodystrophies

2, rue Mi-les-Vignes


Laxou Cedex, 61024


Tel: 33383309334

Fax: 33383300068



NIH/National Institute of Neurological Disorders and Stroke

P.O. Box 5801

Bethesda, MD 20824

Tel: (301)496-5751

Fax: (301)402-2186

Tel: (800)352-9424

TDD: (301)468-5981


Hunter's Hope Foundation, Inc.

PO Box 643

6368 West Quaker Street

Orchard Park, NY 14127

Tel: (716)667-1200

Fax: (716)667-1212

Tel: (877)984-4673



Australian Leukodystrophy Support Group, Inc.

Nerve Centre

54 Railway Road

Blackburn, VIC 3130


Tel: 61395847070

Tel: 1800141400



Pelizaeus Merzbacher Disease Support Group

43 Fir Tree Close


Bedfordshire, MK45 1NY

United Kingdom

Tel: 01525716907



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223


Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766



PMD Foundation

1307 White Horse Road

Suite 603

Voorhees, NJ 08043

Tel: (609)443-9623

Email: or


For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see